Hematopoietic mobilization

Neurology

Volumn 84, Issue 14, 2015, Pages 1473-1482

  Mattoscio, Miriam ^a   Nicholas, Richard ^a,c   Sormani, Maria P ^d   Malik, Omar ^a,c   Lee, Jean S ^c   Waldman, Adam D ^c   Dazzi, Francesco ^b   Muraro, Paolo A ^a  

^a Centre for Neuroscience   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; NATALIZUMAB; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MEMORY CELL; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; REMISSION; STEM CELL MOBILIZATION; ADULT; BLOOD; DRUG EFFECTS; FEMALE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MULTIPLE SCLEROSIS; NATALIZUMAB; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84926672427     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001454     Document Type: Article

References (31)

1. Rose DM, Alon R, Ginsberg MH. Integrin modulation and signaling in leukocyte adhesion and migration. Immunol Rev 2007;218:126-134
2. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390-1401
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354: 899-910
4. Radue EW, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 2010;292:28-35
5. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in expanded disability status scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011;17:970-979
6. Zivadinov R, Dwyer MG, Hussein S, et al. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNbeta-1a in multiple sclerosis. Mult Scler 2012;18:1125-1134
7. Krysko KM, O'Connor PW. The Toronto observational study of natalizumab in multiple sclerosis. Can J Neurol Sci 2011;38:422-428
8. Stuve O, Marra CM, Bar-Or A, et al. Altered CD41/CD81 T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006;63:1383-1387
9. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747
10. Kivisakk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009;72:1922-1930
11. Stuve O. The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci 2008;274:39-41
12. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008;111:3439-3441
13. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD341 hematopoietic progenitor cells in humans. Blood 2008;111:3893-3895
14. Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008;452:442-447
15. Ho J, Kurtz CC, Naganuma M, Ernst PB, Cominelli F, Rivera-Nieves J. A CD81/CD103high T cell subset regulates TNF-mediated chronic murine ileitis. J Immunol 2008;180:2573-2580
16. Uss E, Rowshani AT, Hooibrink B, Lardy NM, van Lier RA, ten Berge IJ. CD103 is a marker for alloantigeninduced regulatory CD81 T cells. J Immunol 2006;177: 2775-2783
17. Jing D, Oelschlaegel U, Ordemann R, et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010;45:1489-1496
18. Saure C, Warnke C, Zohren F, et al. Natalizumab and impedance of the homing of CD341 hematopoietic progenitors. Arch Neurol 2011;68:1428-1431
19. Frohman EM, Monaco MC, Remington G, et al. JC virus in CD341 and CD191 cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014;71:596-602
20. Warnke C, Smolianov V, Dehmel T, et al. CD341 progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 2010;17:151-156
21. Chalkias S, Dang X, Bord E, et al. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol 2014;75:925-934
22. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-923
23. Prosperini L, Gianni C, Barletta V, et al. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci 2012;323:104-112
24. Laroni A, Gandoglia I, Solaro C, et al. Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. BMC Neurol 2014;14:103
25. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405-415
26. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008;71: 1350-1354
27. Lesesve JF, Debouverie M, Decarvalho Bittencourt M, Bene MC. CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes. Bone Marrow Transplant 2011;46: 1489-1491
28. Planas R, Jelcic I, Schippling S, Martin R, Sospedra M. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012;42:790-798
29. Haas J, Bekeredjian-Ding I, Milkova M, et al. B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun 2011;37:289-299
30. Rossi S, Motta C, Studer V, et al. A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation. Mult Scler 2013;19:59-68
31. Zhang L, Bertucci AM, Ramsey-Goldman R, Burt RK, Datta SK. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD81 Treg cells are associated with immunological remission of lupus. J Immunol 2009;183:6346-6358